Dual targeting of HER2 with lapatinib and trastuzumab
Mené sur 455 patientes atteintes d'un cancer du sein HER2+ de stade précoce, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans événement et de la survie globale, et la toxicité d'un traitement néoadjuvant à l'aide de lapatinib, de trastuzumab ou d'une combinaison de ces deux thérapies ciblées
Drugs targeting HER2 are central to the treatment of patients with HER2-positive breast cancer, and dual targeting of HER2 with two drugs has gained much attention since 2010. Patients with metastatic HER2-positive breast cancer have better overall survival when treated with docetaxel and the two anti-HER2 monoclonal antibodies (trastuzumab and pertuzumab, which bind to different extracellular domains of the HER2 kinase), than do patients treated only with docetaxel and trastuzumab. Dual targeti ...
The Lancet Oncology , commentaire, 2013